Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Pharmaceutical Business ReviewThe application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility.RegulatoryOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaceutical Business Review The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. RegulatoryOncologyRead full story Post navigation Previous: Eli Lilly doubles down on in vivo with $7bn Kelonia buyoutNext: FDA kicks off review of Roche’s Gazyva for wider lupus use Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
